Eterna Therapeutics Inc. (ERNA)
Eterna Therapeutics Statistics
Share Statistics
Eterna Therapeutics has 52.24M shares outstanding. The number of shares has increased by 849.57% in one year.
| Shares Outstanding | 52.24M |
| Shares Change (YoY) | 849.57% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 35.44M |
| Failed to Deliver (FTD) Shares | 4.05K |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 44.46K, so 0.09% of the outstanding shares have been sold short.
| Short Interest | 44.46K |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.09% |
| Short Ratio (days to cover) | 1.07 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -0.05. Eterna Therapeutics's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | -0.05 |
| PS Ratio | 6.89 |
| Forward PS | 0.1 |
| PB Ratio | 2.36 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
Eterna Therapeutics Inc. has an Enterprise Value (EV) of 43.83M.
| EV / Earnings | -0.98 |
| EV / Sales | 75.31 |
| EV / EBITDA | -1.21 |
| EV / EBIT | -2.8 |
| EV / FCF | -2.7 |
Financial Position
The company has a current ratio of 0.8, with a Debt / Equity ratio of undefined.
| Current Ratio | 0.8 |
| Quick Ratio | 0.8 |
| Debt / Equity | undefined |
| Total Debt / Capitalization | 28.68 |
| Cash Flow / Debt | -23.15 |
| Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is -26.18% and return on capital (ROIC) is -657.63%.
| Return on Equity (ROE) | -26.18% |
| Return on Assets (ROA) | -8.45% |
| Return on Capital (ROIC) | -657.63% |
| Revenue Per Employee | $97,000 |
| Profits Per Employee | $-7,423,166.67 |
| Employee Count | 6 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 30K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -92.17% in the last 52 weeks. The beta is 7.33, so Eterna Therapeutics's price volatility has been higher than the market average.
| Beta | 7.33 |
| 52-Week Price Change | -92.17% |
| 50-Day Moving Average | 0.32 |
| 200-Day Moving Average | 0.99 |
| Relative Strength Index (RSI) | 26.53 |
| Average Volume (20 Days) | 10.88M |
Income Statement
In the last 12 months, Eterna Therapeutics had revenue of 582K and earned -44.54M in profits. Earnings per share was -3.26.
| Revenue | 582K |
| Gross Profit | 486K |
| Operating Income | -15.67M |
| Net Income | -44.54M |
| EBITDA | -36.12M |
| EBIT | -15.67M |
| Earnings Per Share (EPS) | -3.26 |
Balance Sheet
The company has 1.73M in cash and 684K in debt, giving a net cash position of 1.04M.
| Cash & Cash Equivalents | 1.73M |
| Total Debt | 684K |
| Net Cash | 1.04M |
| Retained Earnings | -231.54M |
| Total Assets | 5.27M |
| Working Capital | -586K |
Cash Flow
In the last 12 months, operating cash flow was -15.84M and capital expenditures -369K, giving a free cash flow of -16.2M.
| Operating Cash Flow | -15.84M |
| Capital Expenditures | -369K |
| Free Cash Flow | -16.2M |
| FCF Per Share | -1.19 |
Margins
Gross margin is 83.51%, with operating and profit margins of -2.69K% and -7.65K%.
| Gross Margin | 83.51% |
| Operating Margin | -2.69K% |
| Pretax Margin | -7.65K% |
| Profit Margin | -7.65K% |
| EBITDA Margin | -6.21K% |
| EBIT Margin | -2.69K% |
| FCF Margin | -2.78K% |
Dividends & Yields
ERNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1811.11% |
| FCF Yield | -168.57% |
Analyst Forecast
Currently there are no analyst rating for ERNA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Oct 17, 2022. It was a backward split with a ratio of 1:20.
| Last Split Date | Oct 17, 2022 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -83.2 |
| Piotroski F-Score | 4 |